TY - JOUR

T1 - The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study

AU - Burisch, Johan

AU - Bergemalm, Daniel

AU - Halfvarson, Jonas

AU - Domislovic, Viktor

AU - Krznaric, Zeljko

AU - Goldis, Adrian

AU - Dahlerup, Jens F

AU - Oksanen, Pia

AU - Collin, Pekka

AU - de Castro, Luisa

AU - Hernandez, Vicent

AU - Turcan, Svetlana

AU - Belousova, Elena

AU - D'Incà, Renata

AU - Sartini, Alessandro

AU - Valpiani, Daniela

AU - Giannotta, Martina

AU - Misra, Ravi

AU - Arebi, Naila

AU - Duricova, Dana

AU - Bortlik, Martin

AU - Gatt, Kelly

AU - Ellul, Pierre

AU - Pedersen, Natalia

AU - Kjeldsen, Jens

AU - Andersen, Karina W

AU - Andersen, Vibeke

AU - Katsanos, Konstantinos H

AU - Christodoulou, Dimitrios K

AU - Sebastian, Shaji

AU - Barros, Luisa

AU - Magro, Fernando

AU - Midjord, Jóngerð Mm

AU - Nielsen, Kári R

AU - Salupere, Riina

AU - Kievit, Hendrika Al

AU - Kiudelis, Gediminas

AU - Kupčinskas, Juozas

AU - Fumery, Mathurin

AU - Gower-Rousseau, Corinne

AU - Kaimakliotis, Ioannis P

AU - Schwartz, Doron

AU - Odes, Selwyn

AU - Lakatos, Laszlo

AU - Lakatos, Peter L

AU - Langholz, Ebbe

AU - Munkholm, Pia

AU - Epi-IBD group

PY - 2020

Y1 - 2020

N2 - BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.

AB - BACKGROUND: The lack of scientific evidence regarding the effectiveness of 5-aminosalicylate in patients with Crohn's disease is in sharp contrast to its widespread use in clinical practice.AIMS: The aim of the study was to investigate the use of 5-aminosalicylate in patients with Crohn's disease as well as the disease course of a subgroup of patients who were treated with 5-aminosalicylate as maintenance monotherapy during the first year of disease.METHODS: In a European community-based inception cohort, 488 patients with Crohn's disease were followed from the time of their diagnosis. Information on clinical data, demographics, disease activity, medical therapy and rates of surgery, cancers and deaths was collected prospectively. Patient management was left to the discretion of the treating gastroenterologists.RESULTS: Overall, 292 (60%) patients with Crohn's disease received 5-aminosalicylate period during follow-up for a median duration of 28 months (interquartile range 6-60). Of these, 78 (16%) patients received 5-aminosalicylate monotherapy during the first year following diagnosis. Patients who received monotherapy with 5-aminosalicylate experienced a mild disease course with only nine (12%) who required hospitalization, surgery, or developed stricturing or penetrating disease, and most never needed more intensive therapy. The remaining 214 patients were treated with 5-aminosalicylate as the first maintenance drug although most eventually needed to step up to other treatments including immunomodulators (75 (35%)), biological therapy (49 (23%)) or surgery (38 (18%)).CONCLUSION: In this European community-based inception cohort of unselected Crohn's disease patients, 5-aminosalicylate was commonly used. A substantial group of these patients experienced a quiescent disease course without need of additional treatment during follow-up. Therefore, despite the controversy regarding the efficacy of 5-aminosalicylate in Crohn's disease, its use seems to result in a satisfying disease course for both patients and physicians.

U2 - 10.1177/2050640620945949

DO - 10.1177/2050640620945949

M3 - Journal article

C2 - 32715989

VL - 8

SP - 949

EP - 960

JO - United European Gastroenterology Journal

JF - United European Gastroenterology Journal

SN - 2050-6406

IS - 8

ER -